Alkermes plc. Net Income
Alkermes plc. (ALKS) reported Net Income of $501.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-07-28
- Alkermes plc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was $501.00K, a 99.42% decline year-over-year.
- Alkermes plc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$66.48M, a 395.94% decline year-over-year.
- Alkermes plc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $49.38M, a 66.30% decline year-over-year.
- Alkermes plc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was $82.76M, a 10.41% decline year-over-year.
- Alkermes plc. net income (loss) attributable to parent for fiscal 2020 was -$110.86M.
- Alkermes plc. net income (loss) attributable to parent for fiscal 2019 was -$196.62M.
- Alkermes plc. net income (loss) attributable to parent for fiscal 2018 was -$139.31M.
- Alkermes plc. net income (loss) attributable to parent for fiscal 2017 was -$157.94M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $501.00K 10-Q · filed 2026-07-28 | -$65.98M 10-Q · filed 2026-07-28 | -$16.60M derived: sum of 3 quarters · filed 2026-07-28 | $66.16M derived: sum of 4 quarters · filed 2026-07-28 | |
| 2026-03-31 | -$66.48M 10-Q · filed 2026-07-28 | -$17.10M derived: sum of 2 quarters · filed 2026-07-28 | $65.66M derived: sum of 3 quarters · filed 2026-07-28 | $152.76M derived: sum of 4 quarters · filed 2026-07-28 | |
| 2025-12-31 | $49.38M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-06 | $132.14M derived: sum of 2 quarters · filed 2026-04-06 | $219.24M derived: sum of 3 quarters · filed 2026-07-28 | $241.70M DEF 14A · filed 2026-04-06 | $241.66M 10-K · filed 2026-02-25 |
| 2025-09-30 | $82.76M 10-Q · filed 2025-10-28 | $169.86M derived: sum of 2 quarters · filed 2026-07-28 | $192.32M 10-Q · filed 2025-10-28 | $338.86M derived: sum of 4 quarters · filed 2026-07-28 | |
| 2025-06-30 | $87.10M 10-Q · filed 2026-07-28 | $109.56M 10-Q · filed 2026-07-28 | $256.10M derived: sum of 3 quarters · filed 2026-07-28 | $348.48M derived: sum of 4 quarters · filed 2026-07-28 | |
| 2025-03-31 | $22.46M 10-Q · filed 2026-07-28 | $169.00M derived: sum of 2 quarters · filed 2026-07-28 | $261.38M derived: sum of 3 quarters · filed 2026-07-28 | $352.74M derived: sum of 4 quarters · filed 2026-07-28 | |
| 2024-12-31 | $146.53M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-06 | $238.91M derived: sum of 2 quarters · filed 2026-04-06 | $330.27M derived: sum of 3 quarters · filed 2026-04-06 | $367.10M DEF 14A · filed 2026-04-06 | $367.07M 10-K · filed 2025-02-12 |
| 2024-09-30 | $92.38M 10-Q · filed 2025-10-28 | $183.74M derived: sum of 2 quarters · filed 2025-10-28 | $220.57M 10-Q · filed 2025-10-28 | $333.39M derived: sum of 4 quarters · filed 2026-04-06 | |
| 2024-06-30 | $91.36M 10-Q · filed 2025-10-28 | $128.19M 10-Q · filed 2025-07-29 | $241.01M derived: sum of 3 quarters · filed 2026-04-06 | $288.77M derived: sum of 4 quarters · filed 2026-04-06 | |
| 2024-03-31 | $36.83M 10-Q · filed 2025-10-28 | $149.65M derived: sum of 2 quarters · filed 2026-04-06 | $197.41M derived: sum of 3 quarters · filed 2026-04-06 | $434.47M derived: sum of 4 quarters · filed 2026-04-06 | |
| 2023-12-31 | $112.82M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-06 | $160.58M derived: sum of 2 quarters · filed 2026-04-06 | $397.64M derived: sum of 3 quarters · filed 2026-04-06 | $355.80M DEF 14A · filed 2026-04-06 | $355.76M 10-K · filed 2024-02-21 |
| 2023-09-30 | $47.76M 10-Q · filed 2024-10-24 | $284.82M derived: sum of 2 quarters · filed 2024-10-24 | $242.98M 10-Q · filed 2024-10-24 | $214.69M derived: sum of 4 quarters · filed 2026-04-06 | |
| 2023-06-30 | $237.06M 10-Q · filed 2024-10-24 | $195.22M 10-Q · filed 2024-07-24 | $166.93M derived: sum of 3 quarters · filed 2026-04-06 | $102.96M derived: sum of 4 quarters · filed 2026-04-06 | |
| 2023-03-31 | -$41.84M 10-Q · filed 2024-10-24 | -$70.13M derived: sum of 2 quarters · filed 2026-04-06 | -$134.11M derived: sum of 3 quarters · filed 2026-04-06 | -$164.24M derived: sum of 4 quarters · filed 2026-04-06 | |
| 2022-12-31 | -$28.29M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-06 | -$92.26M derived: sum of 2 quarters · filed 2026-04-06 | -$122.40M derived: sum of 3 quarters · filed 2026-04-06 | -$158.30M DEF 14A · filed 2026-04-06 | -$158.27M 10-K · filed 2023-02-16 |
| 2022-09-30 | -$63.97M 10-Q · filed 2023-10-25 | -$94.11M derived: sum of 2 quarters · filed 2023-10-25 | -$130.01M 10-Q · filed 2023-10-25 | -$129.17M derived: sum of 4 quarters · filed 2026-04-06 | |
| 2022-06-30 | -$30.14M 10-Q · filed 2023-10-25 | -$66.04M 10-Q · filed 2023-07-26 | -$65.20M derived: sum of 3 quarters · filed 2026-04-06 | -$94.19M derived: sum of 4 quarters · filed 2026-04-06 | |
| 2022-03-31 | -$35.90M 10-Q · filed 2023-10-25 | -$35.06M derived: sum of 2 quarters · filed 2026-04-06 | -$64.05M derived: sum of 3 quarters · filed 2026-04-06 | -$61.69M derived: sum of 4 quarters · filed 2026-04-06 | |
| 2021-12-31 | $842.00K derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-06 | -$28.15M derived: sum of 2 quarters · filed 2026-04-06 | -$25.78M derived: sum of 3 quarters · filed 2026-04-06 | -$48.20M DEF 14A · filed 2026-04-06 | -$48.17M 10-K · filed 2022-02-16 |
| 2021-09-30 | -$28.99M 10-Q · filed 2022-11-02 | -$26.62M derived: sum of 2 quarters · filed 2022-11-02 | -$49.04M 10-Q · filed 2022-11-02 | -$91.68M derived: sum of 4 quarters · filed 2023-02-16 | |
| 2021-06-30 | $2.36M 10-Q · filed 2022-11-02 | -$20.05M 10-Q · filed 2022-07-27 | -$62.70M derived: sum of 3 quarters · filed 2023-02-16 | -$62.83M derived: sum of 4 quarters · filed 2023-02-16 | |
| 2021-03-31 | -$22.42M 10-Q · filed 2022-11-02 | -$65.06M derived: sum of 2 quarters · filed 2023-02-16 | -$65.19M derived: sum of 3 quarters · filed 2023-02-16 | -$94.63M derived: sum of 4 quarters · filed 2023-02-16 | |
| 2020-12-31 | -$42.64M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | -$42.78M derived: sum of 2 quarters · filed 2023-02-16 | -$72.21M derived: sum of 3 quarters · filed 2023-02-16 | -$110.86M 10-K · filed 2023-02-16 | |
| 2020-09-30 | -$134.00K 10-Q · filed 2021-10-27 | -$29.57M derived: sum of 2 quarters · filed 2021-10-27 | -$68.22M 10-Q · filed 2021-10-27 | -$73.57M derived: sum of 4 quarters · filed 2022-02-16 | |
| 2020-06-30 | -$29.43M 10-Q · filed 2021-10-27 | -$68.08M 10-Q · filed 2021-07-28 | -$73.44M derived: sum of 3 quarters · filed 2022-02-16 | -$126.32M derived: sum of 4 quarters · filed 2022-02-16 | |
| 2020-03-31 | -$38.65M 10-Q · filed 2021-10-27 | -$44.01M derived: sum of 2 quarters · filed 2022-02-16 | -$96.89M derived: sum of 3 quarters · filed 2022-02-16 | -$138.88M derived: sum of 4 quarters · filed 2022-02-16 | |
| 2019-12-31 | -$5.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | -$58.23M derived: sum of 2 quarters · filed 2022-02-16 | -$100.22M derived: sum of 3 quarters · filed 2022-02-16 | -$196.62M 10-K · filed 2022-02-16 | |
| 2019-09-30 | -$52.88M 10-Q · filed 2020-10-29 | -$94.87M derived: sum of 2 quarters · filed 2020-10-29 | -$191.27M 10-Q · filed 2020-10-29 | -$200.98M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-06-30 | -$41.99M 10-Q · filed 2020-10-29 | -$138.39M 10-Q · filed 2020-07-29 | -$148.10M derived: sum of 3 quarters · filed 2021-02-11 | -$182.54M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-03-31 | -$96.40M 10-Q · filed 2020-10-29 | -$106.11M derived: sum of 2 quarters · filed 2021-02-11 | -$140.56M derived: sum of 3 quarters · filed 2021-02-11 | -$173.20M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2018-12-31 | -$9.71M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$44.16M derived: sum of 2 quarters · filed 2021-02-11 | -$76.81M derived: sum of 3 quarters · filed 2021-02-11 | -$139.31M 10-K · filed 2021-02-11 | |
| 2018-09-30 | -$34.44M 10-Q · filed 2019-10-23 | -$67.09M derived: sum of 2 quarters · filed 2019-10-23 | -$129.60M 10-Q · filed 2019-10-23 | ||
| 2018-06-30 | -$32.65M 10-Q · filed 2019-10-23 | -$95.15M 10-Q · filed 2019-07-25 | |||
| 2018-03-31 | -$62.51M 10-Q · filed 2019-10-23 | ||||
| 2017-12-31 | -$157.94M 10-K · filed 2020-02-13 | ||||
| 2016-12-31 | -$208.44M 10-K · filed 2019-02-15 | ||||
| 2015-12-31 | -$227.16M 10-K · filed 2018-02-16 | ||||
| 2014-12-31 | -$30.06M 10-K · filed 2017-02-17 | ||||
| 2013-12-31 | $17.65M 10-K · filed 2016-02-25 | ||||
| 2013-03-31 | $24.98M 10-K · filed 2015-02-24 | ||||
| 2012-03-31 | -$63.36M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | -$78.19M derived: sum of 2 quarters · filed 2014-02-27 | -$100.44M derived: sum of 3 quarters · filed 2014-02-27 | -$113.68M 10-KT · filed 2014-02-27 | |
| 2011-12-31 | -$14.83M 10-Q · filed 2012-02-02 | -$37.08M derived: sum of 2 quarters · filed 2012-02-02 | -$50.32M 10-Q · filed 2012-02-02 | ||
| 2011-09-30 | -$22.25M 10-Q · filed 2011-11-03 | -$35.49M 10-Q · filed 2011-11-03 | |||
| 2011-03-31 | -$13.08M derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-23 | -$24.46M derived: sum of 2 quarters · filed 2013-05-23 | -$32.13M derived: sum of 3 quarters · filed 2013-05-23 | -$45.54M 10-K · filed 2013-05-23 | |
| 2010-12-31 | -$11.38M 10-Q · filed 2012-02-02 | -$19.05M derived: sum of 2 quarters · filed 2012-02-02 | -$32.46M 10-Q · filed 2012-02-02 | ||
| 2010-09-30 | -$7.67M 10-Q · filed 2011-11-03 | -$21.07M 10-Q · filed 2011-11-03 | |||
| 2010-03-31 | -$39.63M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |